5-(4-nitrophenyl)-3,4-dihydroazepino[3,4,5-hi]indolizin-1(2H)-one | 1187318-07-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 5-(4-nitrophenyl)-3,4-dihydroazepino[3,4,5-hi]indolizin-1(2H)-one
• 英文别名: 2-(4-Nitrophenyl)-4,10-diazatricyclo[6.4.1.04,13]trideca-1(13),2,5,7-tetraen-9-one
• CAS: 1187318-07-5
• 化学式: C₁₇H₁₃N₃O₃
• 分子量: 307.309
• InChiKey: BNKRNLAPNNCMDJ-UHFFFAOYSA-N

物化性质

• 密度：
  1.46±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  79.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(4-nitrophenyl)-3,4-dihydroazepino[3,4,5-hi]indolizin-1(2H)-one 在 水 、 铁粉 、 氯化铵 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 N2,N2-dimethyl-N-[4-(1-oxo-1,2,3,4-tetrahydroazepino[3,4,5-hi]indolizin-5-yl)phenyl]glycinamide
  参考文献：
  名称：

  [EN] TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
  [FR] DÉRIVÉS TRICYCLIQUES EN TANT QU'INHIBITEURS DE POLY(ADP-RIBOSE)POLYMÉRASE (PARP)

  摘要：

  本发明涉及式(I)的化合物及其药用可接受的盐或互变异构体，它们是聚(ADP-核糖)聚合酶(PARP)的抑制剂，因此可用于治疗癌症、炎症性疾病、再灌注损伤、缺血症状、中风、肾衰竭、心血管疾病、除心血管疾病外的血管疾病、糖尿病、神经退行性疾病、逆转录病毒感染、视网膜损伤、皮肤衰老和紫外线诱导的皮肤损伤，以及作为癌症治疗的化疗或放射敏感剂。

  公开号：

  WO2009112832A1
• 作为产物：
  描述：

  2-溴烟酸 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 palladium 10% on activated carbon 氢气 、 sodium methylate 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 甲苯 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 71.0h， 生成 5-(4-nitrophenyl)-3,4-dihydroazepino[3,4,5-hi]indolizin-1(2H)-one
  参考文献：
  名称：

  [EN] TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
  [FR] DÉRIVÉS TRICYCLIQUES EN TANT QU'INHIBITEURS DE POLY(ADP-RIBOSE)POLYMÉRASE (PARP)

  摘要：

  本发明涉及式(I)的化合物及其药用可接受的盐或互变异构体，它们是聚(ADP-核糖)聚合酶(PARP)的抑制剂，因此可用于治疗癌症、炎症性疾病、再灌注损伤、缺血症状、中风、肾衰竭、心血管疾病、除心血管疾病外的血管疾病、糖尿病、神经退行性疾病、逆转录病毒感染、视网膜损伤、皮肤衰老和紫外线诱导的皮肤损伤，以及作为癌症治疗的化疗或放射敏感剂。

  公开号：

  WO2009112832A1

文献信息

• TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)
  申请人：Ingenito Raffaele

  公开号：US20110053911A1

  公开（公告）日：2011-03-03

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.

  本发明涉及式（I）化合物及其药学上可接受的盐或互变异构体，它们是聚（ADP核糖）聚合酶（PARP）抑制剂，因此可用于治疗癌症、炎症性疾病、再灌注损伤、缺血症、中风、肾衰竭、心血管疾病、非心血管疾病的血管疾病、糖尿病、神经退行性疾病、逆转录病毒感染、视网膜损伤、皮肤衰老和紫外线引起的皮肤损伤的治疗药物，以及作为癌症治疗的化疗或放射增敏剂。
• USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES
  申请人：DelMar Pharmaceuticals, Inc.

  公开号：US20180071244A1

  公开（公告）日：2018-03-15

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of malignancies of the central nervous system in pediatric patients, including glioblastoma multiforme (GBM) high grade glioma, and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N 7 methylation and that can induce double-stranded breaks in DNA. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents (e.g. cisplatin) and can possess additive or super-additive effects.
• USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER
  申请人：Bacha Jeffrey A.

  公开号：US20190091195A1

  公开（公告）日：2019-03-28

  Substituted hexitol derivatives such as dianhydrogalactitol are useful in the treatment of various neoplastic pathologies. Said pathologies include glioblastoma multiforme, non-small-cell lung carcinoma (NSCLC), ovarian cancer, and leptomeningeal carcinomatosis. The anti-neoplastic activity of dianhydrogalactitol is demonstrated to be due to its activity as an alkylating agent that creates N 7 methylation and inter-strand DNA crosslinks. The hexitol derivatives may be used alone or in combination with other anti-neoplastic agents.
• US8362030B2
  申请人：——

  公开号：US8362030B2

  公开（公告）日：2013-01-29
• [EN] TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)<br/>[FR] DÉRIVÉS TRICYCLIQUES EN TANT QU'INHIBITEURS DE POLY(ADP-RIBOSE)POLYMÉRASE (PARP)
  申请人：ANGELETTI P IST RICHERCHE BIO

  公开号：WO2009112832A1

  公开（公告）日：2009-09-17

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo-or radiosensitizers for cancer treatment.

  本发明涉及式(I)的化合物及其药用可接受的盐或互变异构体，它们是聚(ADP-核糖)聚合酶(PARP)的抑制剂，因此可用于治疗癌症、炎症性疾病、再灌注损伤、缺血症状、中风、肾衰竭、心血管疾病、除心血管疾病外的血管疾病、糖尿病、神经退行性疾病、逆转录病毒感染、视网膜损伤、皮肤衰老和紫外线诱导的皮肤损伤，以及作为癌症治疗的化疗或放射敏感剂。